Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew E Kennedy

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry|March 4, 2016
Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman PrimatesMihirbaran Mandal, Yusheng Wu, Jeffrey Misiaszek, et al.
Science Translational Medicine|April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficitsMarco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Journal of Medicinal Chemistry|December 30, 2021
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 InhibitorsMitchell H Keylor, Anmol Gulati, Solomon D Kattar, et al.
Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|October 20, 2023
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's DiseaseSolomon D Kattar, Anmol Gulati, Kaila A Margrey, et al.
Journal of Medicinal Chemistry|March 4, 2016
Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman PrimatesMihirbaran Mandal, Yusheng Wu, Jeffrey Misiaszek, et al.
Science Translational Medicine|April 24, 2020
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficitsMarco A S Baptista, Kalpana Merchant, Ted Barrett, et al.
Journal of Medicinal Chemistry|September 4, 2024
Discovery and Optimization of N-Heteroaryl Indazole LRRK2 InhibitorsKaitlyn M Logan, Will Kaplan, Vladimir Simov, et al.
Journal of Medicinal Chemistry|December 30, 2021
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 InhibitorsMitchell H Keylor, Anmol Gulati, Solomon D Kattar, et al.
Journal of Medicinal Chemistry|March 1, 2017
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D Scott, Duane E DeMong, Thomas J Greshock, et al.
Journal of Medicinal Chemistry|December 8, 2022
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1<i>H</i>-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's DiseaseDavid A Candito, Vladimir Simov, Anmol Gulati, et al.
Pageof 4